吡格列酮治疗糖尿病肾病的疗效观察

Pioglitazone treatment of diabetic nephropathy

目的探讨吡格列酮对糖尿病患者的临床疗效和对肾脏的保护作用。方法选取早期糖尿病肾病患者50例,在原控制血糖方案基础上加用罗格列酮30 mg/d,观察3个月,治疗前后分别检测患者空腹血糖(FBG)、糖化血红蛋白(HbA1c)、收缩压(SBP)、舒张压(DBP)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、尿微量白蛋白排泄率(UAER)、C-反应蛋白(CRP)、c肽。结果患者FBG、HbA1c、SBP、DBP、TG、UAER、CRP、c肽下降及HDL-C上升,具有统计学意义。结论吡格列酮治疗糖尿病肾病效果显著,在降糖的同时亦可减少尿蛋白排泄,有一定的肾脏保护作用。

Objective To explore the dinical efficay of Piolitazone in diabetic patients and its protective effects on the kidney. Methods 50 cases of patients with early diabetic nephropathy, in the original pro- gram on the basis of glycemic control with rosiglitazone plus 30 mg / d, observed for 3 months before and after treatment were detected in patients with fasting blood glucose （FBG）, glycosylated hemoglobin （HbAl c）, sys- tolic pressure （SBP）, diastolic blood pressure （DBP）, triglyceride （TG）, high-density lipoprotein cholesterol （HDL-C）, urinary albumin excretion rate （UAER）, C-reactive protein （CRP）, c-peptide . Results Pa- tients with FBG, HbAlc, SBP, DBP, TG, UAER, CRP, c-peptide decreased and HDL-C increased, with sta- tistical significance. Conclusion Pioglitazone treatment of diabetic nephropathy results are obvious, in the hypoglycemic, while also reducing urinary protein excretion, there is a certain degree of renal protection.